Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity

The NETTER-1 trial demonstrated significantly improved progression-free survival (PFS) for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET) emphasizing the high demand for response prediction in appropriate candidates. In this multicenter study, we aimed to elucidate the p...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Werner, Rudolf A., Lapa, Constantin, Ilhan, Harun, Higuchi, Takahiro, Buck, Andreas K., Lehner, Sebastian, Bartenstein, Peter, Bengel, Frank, Schatka, Imke, Muegge, Dirk O., Papp, László, Zsótér, Norbert, Große-Ophoff, Tobias, Essler, Markus, Bundschuh, Ralph A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2016
Soggetti:
Clinical Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5351689/
https://ncbi.nlm.nih.gov/pubmed/27705948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12402
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi